Loading...
•
Mar 31, 2021
Aldeyra Q1 2021 Earnings Report
Aldeyra reported financial results for the first quarter of 2021 and provided recent business highlights.
Key Takeaways
Aldeyra Therapeutics reported a net loss of $11.3 million for the quarter ended March 31, 2021, compared to a net loss of $9.9 million for the same period in 2020. The company's cash and cash equivalents were $138.4 million as of March 31, 2021.
Phase 3 INVIGORATE clinical trial results indicated statistically significant activity of reproxalap in ocular itching and redness associated with allergic conjunctivitis.
Top-line results from Phase 3 TRANQUILITY and TRANQUILITY-2 trials of reproxalap in dry eye disease expected in the second half of 2021.
Initial Phase 2 clinical trial results for ADX-629, a novel orally available systems-based RASP inhibitor, expected in the second half of 2021.
Raised gross proceeds of $125 million in an underwritten public offering.
Forward Guidance
Aldeyra expects to have sufficient capital to prepare reproxalap for NDA submission and a potential commercial launch, if approved, while investing in the clinical development of ADX-629, ADX-2191, and other product candidates in retinal and systemic immunological diseases with unmet medical need.
Positive Outlook
- Sufficient capital to prepare reproxalap for NDA submission
- Potential commercial launch of reproxalap, if approved
- Investing in the clinical development of ADX-629
- Investing in the clinical development of ADX-2191
- Continued development of product candidates in retinal and systemic immunological diseases
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...